Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

NCT07063823 is registered in ClinicalTrials.gov with Nielsen Fernandez-Becker as lead sponsor.

NCT NCT07063823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07063823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
Lead sponsor
Nielsen Fernandez-Becker
Phase
Phase 1
Overall status
Completed
Start date
August 26, 2025
Completion date
April 7, 2026
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

celiac disease, healthy